AAD

AngloGold Ashanti plc Completes the Primary Listing of Its Ordinary Shares on the NYSE and Commences Trading

Retrieved on: 
Monday, September 25, 2023

The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August.

Key Points: 
  • The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August.
  • Trading in the AngloGold Ashanti Limited American Depositary Shares (ADSs) on the NYSE ceased at the close of market on 22 September 2023 and the AngloGold Ashanti Limited ADS program has been terminated with effect from today.
  • The ordinary shares of AngloGold Ashanti plc commenced trading on the JSE and A2X on 20 September 2023, maintaining the ticker symbol ANG.
  • The ordinary shares and Ghanaian Depositary Shares of AngloGold Ashanti plc will commence trading on the GhSE, maintaining the ticker symbols AGA and AAD, respectively, on 26 September 2023.

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, September 12, 2023

SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.

Key Points: 
  • SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.
  • “We also reported positive long-term data from the Phase 2 maintenance period in ulcerative colitis with our other late-stage asset – icanbelimod.
  • There were no new safety signals and icanbelimod continued to be well-tolerated, consistent with observed induction period safety data.
  • Published in July 2023 the pre-clinical data characterizing rademikibart in Nature’s Scientific Reports.

Tool Sprawl, External Threats, and Security Are Top Concerns for IT Admins

Retrieved on: 
Tuesday, September 12, 2023

While 77% of SME IT admins want a single tool to do their job, organizations continue to force them to use many more.

Key Points: 
  • While 77% of SME IT admins want a single tool to do their job, organizations continue to force them to use many more.
  • In terms of coming layoffs, 77% of all admins anticipate more layoffs, in line with 78% of US-only admins who anticipate the same.
  • 49% of admins agree that they’re more concerned about their organization’s security posture now than they were six months ago.
  • While male and female admins report the same general level of happiness in their job, more male admins (61%) report feeling overwhelmed than female admins (53%).

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

Retrieved on: 
Monday, September 11, 2023

Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America

Key Points: 
  • Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America
    INCHEON, Korea, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai (ustekinumab), marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States (US), Canada, European Economic Area (EEA), Switzerland and United Kingdom (UK).
  • “This agreement is a testament to Samsung Bioepis’ strong track record in the field of immunology, demonstrating a potential value that our biosimilars could deliver for widening access to biologic medicines.” said Sang-Jin Pak, Executive Vice President and Head of Commercial Division, at Samsung Bioepis.
  • SB17, a proposed biosimilar to Stelara (ustekinumab), is Samsung Bioepis’ fourth candidate in its immunology pipeline, following SB4 (etanercept), SB2 (infliximab) and SB5 (adalimumab).
  • Samsung Bioepis has a more than 5-year track record of supplying over 48 million units of immunology biosimilars in nearly 40 markets across the world.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO MAKE MELASMA LESS NOTICEABLE

Retrieved on: 
Tuesday, September 12, 2023

ROSEMONT, Ill., Sept. 12, 2023 /PRNewswire/ -- Melasma is a skin condition that causes patches or large, freckle-like spots on the face that are darker than a person's natural skin color. Melasma has many causes, including sun exposure, pregnancy, stress, a medical condition, or taking certain medications, such as oral contraceptive pills.

Key Points: 
  • Melasma has many causes, including sun exposure, pregnancy, stress, a medical condition, or taking certain medications, such as oral contraceptive pills.
  • Because the cells that give the skin its color – melanocytes – are more active, melasma can be more noticeable in people with darker skin tones.
  • "While melasma may go away on its own, it can persist for years," said Rebecca Kazin, MD, FAAD, a board-certified dermatologist in Rockville, Md.
  • Covering an uneven skin tone caused by melasma may make your melasma less noticeable if the appearance bothers you.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

Retrieved on: 
Thursday, August 10, 2023

WEST CHESTER, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of lesion clearance data from Part 1 of an ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC). The presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and highlights the antitumor response of VP-315 as determined by clinical and histological clearance of treated BCC lesions. Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego and Principal Investigator for the study, presented the data at the 2023 American Academy of Dermatology Innovation Academy, which is being held from August 10-13th, in Tampa, FL.

Key Points: 
  • The presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and highlights the antitumor response of VP-315 as determined by clinical and histological clearance of treated BCC lesions.
  • Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego and Principal Investigator for the study, presented the data at the 2023 American Academy of Dermatology Innovation Academy, which is being held from August 10-13th, in Tampa, FL.
  • The other 2 subjects showed a partial response in tumor burden reduction (95% tumor clearance and 30% tumor clearance).
  • “We are pleased to report these encouraging results for our novel oncolytic peptide therapy, VP-315, in basal cell carcinoma at this year’s American Academy of Dermatology Innovation Academy,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals.

Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

Retrieved on: 
Tuesday, August 8, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230804756518/en/
    Nitika, living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “I was young when I was diagnosed with moderate to severe plaque psoriasis, and it felt like my whole life revolved around my condition.
  • “This insight drove us to launch the Clear Understanding campaign to recognize those concessions and encourage people living with moderate to severe plaque psoriasis to talk to their dermatologist about available treatment options."
  • In two studies of moderate to severe plaque psoriasis, Sotyktu was compared to placebo and Otezla® (apremilast).

Acclaro Medical Launches UltraClear Laser-Coring Treatment at 2023 International Dermatology Meetings

Retrieved on: 
Thursday, August 3, 2023

SMITHFIELD, R.I. , Aug. 3, 2023 /PRNewswire/ -- Acclaro Medical, an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced the launch of UltraClear Laser-Coring, the first-of-its-kind laser to enable tissue coring to improve deep wrinkles, deep scars, and other age-related issues on all skin types with minimal discomfort and downtime. The newest UltraClear mode provides a breakthrough in collagen remodeling by combining fractional tissue coring and laser rejuvenation without scalpels or sutures in about 30 minutes.

Key Points: 
  • The newest UltraClear mode provides a breakthrough in collagen remodeling by combining fractional tissue coring and laser rejuvenation without scalpels or sutures in about 30 minutes.
  • Speaking at the 2023 AAD Innovation Academy, leading aesthetic dermatologist Dr. David Friedman will present his clinical journey to optimize UltraClear's dermal tissue coring using high-resolution vaporizing and heating effects to achieve fast collagen contraction and remarkable cosmetic outcomes.
  • He will also share an array of noteworthy patient before and after photos that demonstrate his expertise at tailoring UltraClear anti-aging treatments to individual patient needs and desires.
  • Earlier this summer, renowned laser dermatologist Dr. Paul Friedman, Houston, TX, introduced the fundamentals of UltraClear Laser-Coring technology to great acclaim during his Next Level Webinar.

Anne Arundel Dermatology Names Vincent Bradley as Chief Executive Officer

Retrieved on: 
Wednesday, August 2, 2023

Anne Arundel Dermatology (“AAD”), a leading provider of medical, surgical and cosmetic dermatological services, announced that Vincent Bradley has been named Chief Executive Officer.

Key Points: 
  • Anne Arundel Dermatology (“AAD”), a leading provider of medical, surgical and cosmetic dermatological services, announced that Vincent Bradley has been named Chief Executive Officer.
  • Mr. Bradley has 20 years of experience across multiple specialties within healthcare service organizations, including primary care, women’s health and veterinary medicine.
  • As an entrepreneur and business operator, he has chief executive experience leading scaled, multi-unit healthcare provider platforms through strategic growth planning and team building initiatives.
  • “I am excited to join the Anne Arundel Dermatology team and continue to build upon an exceptional track record of clinical excellence and successful collaboration with our affiliated practices,” said Mr. Bradley.